The latest study released on the global ‘Artificial Intelligence In Genomics’ market by AMA Research evaluates market size, trend, and forecast to 2030. The ‘Artificial Intelligence In Genomics’ market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analyzed study to help understand market trends, growth drivers, opportunities and upcoming challenges and about the competitors.
Get free access to Sample Report in PDF Version along with Graphs and Figures @ https://www.advancemarketanalytics.com/sample-report/173521-global-artificial-intelligence-in-genomics-market?utm_source=LinkedIn/utm_medium=Rahul
Some of the key players profiled in the study are:
IBM Corporation (United States), Microsoft Corporation (United States), NVIDIA Corporation (United States), Deep Genomics (Canada), BenevolentAI (United Kingdom), Fabric Genomics Inc. (United States), Verge Genomics (United States), Cambridge Cancer Genomics (United Kingdom), Sophia Genetics (United States), Data4Cure Inc. (United States),
Although genomic medicine has achieved great advances in recent years, the clinical use of genomics is still evolving as new understanding and technology emerge. One key problem is making sense of exceptionally huge amounts of genomic sequence data and properly integrating and examining it with other relevant information, such as other molecular or clinical data. AI-based computer vision methods are set to change image-based diagnostics in clinical diagnostics, while other AI subtypes have begun to show comparable promise in diverse diagnostic modalities. Deep learning is a sort of AI technique that is used to handle vast and complicated genomic datasets in particular fields, such as clinical genomics.
On 17th December, 2020 – Illumina, Emedgene Launch AI-Based Rare Disease Interpretation Partnership to Integrate Automated Interpretation of Rare Genetic Disease Data into Illumina’s TruSight Software Suite.
Keep yourself up-to-date with latest market trends and changing dynamics due to COVID Impact and Economic Slowdown globally. Maintain a competitive edge by sizing up with available business opportunity in Artificial Intelligence In Genomics Market various segments and emerging territory.
Influencing Market Trend
- Rising Adoption of AI in Precision Medicine Segment
Market Drivers
- High Investments in AI for Genomics
- Growth in Healthcare Infrastructure
Opportunities:
- Increasing Penetration Across Emerging regions
Challenges:
- Data Theft or Leakage
- High Initial Investment
Analysis by Application (Diagnostics, Drug Discovery & Development, Precision Medicine, Agriculture & Animal Research, Other), Technology (Deep Learning, Reinforcement Learning, Supervised Learning, Unsupervised Learning, Others), End Use (Hospitals, Specialty Clinics), Functions (Genome Sequencing, Gene Editing, Clinical Workflows, Predictive Genetic Testing), Component (Software, Services (Managed, Professional))
Have Any Questions Regarding Global Artificial Intelligence In Genomics Market Report, Ask Our Experts@ https://www.advancemarketanalytics.com/enquiry-before-buy/173521-global-artificial-intelligence-in-genomics-market?utm_source=LinkedIn/utm_medium=Rahul
The regional analysis of Global Artificial Intelligence In Genomics Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading region across the world. Whereas, owing to rising no. of research activities in countries such as China, India, and Japan, Asia Pacific region is also expected to exhibit higher growth rate the forecast period 2024-2030.
On 11th July, 2019 – Invitae Acquired Jungla (Leading Artificial Intelligence-Driven Biotech Firm) Valued at USD $65M. The Deal Adds Functional Modeling Platform, which uses Machine Learning to Integrate Functional & Computational Data to Create Predictive Models That Can Be Used to Interpret the Clinical Significance of Genomic Variants.
On 16th April, 2021 – Relay Therapeutics Completed its Acquisition of ZebiAI, for USD $85M. The Deal Combines ZebiAI Technology that applies ML to DNA-Encoded Libraries and Predicts the Small Molecules with The Potential to Drug Proteins, with Relay’s Dynamo Technology across Genomics Portfolio.
Table of Content
Chapter One: Industry Overview
Chapter Two: Major Segmentation (Classification, Application and etc.) Analysis
Chapter Three: Production Market Analysis
Chapter Four: Sales Market Analysis
Chapter Five: Consumption Market Analysis
Chapter Six: Production, Sales and Consumption Market Comparison Analysis
Chapter Seven: Major Manufacturers Production and Sales Market Comparison Analysis
Chapter Eight: Competition Analysis by Players
Chapter Nine: Marketing Channel Analysis
Chapter Ten: New Project Investment Feasibility Analysis
Chapter Eleven: Manufacturing Cost Analysis
Chapter Twelve: Industrial Chain, Sourcing Strategy and Downstream Buyers
Read Executive Summary and Detailed Index of full Research Study @ https://www.advancemarketanalytics.com/reports/173521-global-artificial-intelligence-in-genomics-market?utm_source=LinkedIn/utm_medium=Rahul
Highlights of the Report
• The future prospects of the global Artificial Intelligence In Genomics market during the forecast period 2024-2030 are given in the report.
• The major developmental strategies integrated by the leading players to sustain a competitive market position in the market are included in the report.
• The emerging technologies that are driving the growth of the market are highlighted in the report.
• The market value of the segments that are leading the market and the sub-segments are mentioned in the report.
• The report studies the leading manufacturers and other players entering the global Artificial Intelligence In Genomics market.
